



(43) International Publication Date
25 September 2014 (25.09.2014)

(51) International Patent Classification:

C07D 487/04 (2006.01) *A61P 7/00* (2006.01)
A61K 31/437 (2006.01)

(21) International Application Number:

PCT/US2014/022789

(22) International Filing Date:

10 March 2014 (10.03.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

13/815,770	15 March 2013 (15.03.2013)	US
61/905,802	18 November 2013 (18.11.2013)	US
61/905,803	18 November 2013 (18.11.2013)	US

(71) Applicant: **GLOBAL BLOOD THERAPEUTICS, INC.**
[US/US]; 400 East Jamie Court, Suite 101, South San Francisco, California 94080 (US).

(72) Inventors: **METCALF, Brian W.**; c/o Global Blood Therapeutics, Inc., 400 East Jamie Court, Suite 101, South San Francisco, California 94080 (US). **LI, Zhe**; c/o Global Blood Therapeutics, Inc., 400 East Jamie Court, Suite 101, South San Francisco, California 94080 (US). **XU, Qing**; c/o Global Blood Therapeutics, Inc., 400 East Jamie Court, Suite 101, South San Francisco, California 94080 (US). **GWALTNEY, Stephen L., II**; c/o Global Blood Therapeutics, Inc., 400 East Jamie Court, Suite 101, South San Francisco, California 94080 (US). **HARRIS, Jason R.**; c/o Global Blood Therapeutics, Inc., 400 East Jamie Court, Suite 101, South San Francisco, California 94080 (US). **YEE, Calvin W.**; c/o Global Blood Therapeutics, Inc., 400 East Jamie Court, Suite 101, South San Francisco, California 94080 (US).

(74) Agents: **SWISS, Gerald F.** et al.; c/o Foley & Lardner LLP, 3000 K Street N.W., Suite 600, Washington, District of Columbia 20007-5109 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) Title: COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN

(57) Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.

